Trials / Completed
CompletedNCT00368069
A Study to Look at the Efficacy and Safety of Keppra® Extended Release Formulation - XR
A Double-blind, Placebo-controlled, Randomized Efficacy and Safety Study of Keppra® Extended Release Formulation - XR Once Daily as add-on Therapy in Subjects From 12 to 70 Years With Refractory Epilepsy Suffering From Partial Onset Seizures.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 158 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 12 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study of Keppra® extended release formulation - XR in patients with epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Keppra® extended release formulation - XR | 500mg extended release oral tablet, 2 tablets once daily |
| DRUG | Placebo | oral tablets, 2 tablets once daily |
Timeline
- Start date
- 2006-08-01
- Primary completion
- 2007-05-01
- Completion
- 2007-05-01
- First posted
- 2006-08-24
- Last updated
- 2020-07-15
- Results posted
- 2009-07-28
Locations
34 sites across 7 countries: Brazil, Finland, India, Mexico, Russia, South Africa, Ukraine
Source: ClinicalTrials.gov record NCT00368069. Inclusion in this directory is not an endorsement.